Project Grant R43CA285125
Award Date
9/26/23
Completion Date
8/31/24
Dollars Obligated
$407K
Federal Agency
National Cancer Institute
Awardee
Rahimzadeh Jason (VX76ADAYUNC5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,172,978 Phase II Small Business Innovation Research (SBIR) grant to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The key objectives of this 2-year project are to: 1) finalize the system design and verify it meets all requirements...
This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $703,540.00 to Brigham & Women's Hospital Inc. to develop and optimize highly effective treatments for head and neck cancer using in situ implantable microdevices. The primary goals are to: Conduct a clinical study to validate the performance of the microdevice in predicting patients' clinical response to immunotherapy and chemotherapy for head and neck squamous cell...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization based in Pittsburgh, Pennsylvania. The purpose of this 5-year grant (award date: September 18, 2024) is to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $400,000 to Argosmd, Inc. to develop a low-cost, portable "Mini-Reflectance Confocal Microscope" (Mini-RCM) device to aid in skin cancer diagnosis and treatment. The project aims to create an improved Mini-RCM device with wide-field imaging capability and a compact, dermatoscope-like form factor. This is intended to address limitations of current...
The federal Project Grant award R21CA297246 was provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Dartmouth-Hitchcock Clinic, a non-profit healthcare provider and academic medical center. The $226,704 award, granted from January 1, 2025 to December 31, 2026, supports research to develop a novel magnetic nanoparticle heating system that uses low-frequency alternating magnetic fields to efficiently deliver energy to nanoparticles...
This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,899 to Emory University to develop an innovative platform for conformal flash proton therapy to treat central lung cancer. The key products and services to be delivered include: Establishing a Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform to inversely solve the variables (intensity and energy) of the Integrated Physical Optimization...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...